RNAC Q3 2024 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$387,000-94.1% YoY

Gross Profit

$387,000100.0% margin

Operating Income

-$18M-4541.3% margin

Net Income

-$24M-6248.8% margin

EPS (Diluted)

$-1.13

QoQ Revenue Growth

-98.8%

Cash Flow

Operating Cash Flow

$14M

Free Cash Flow

$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$455M

Total Liabilities

$455M

Stockholders' Equity

$752,000

Cash & Equivalents

$219M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$387,000	$7M	-94.1%
Gross Profit	$387,000	-$6M	+106.0%
Operating Income	-$18M	-$13M	-34.5%
Net Income	-$24M	-$9M	-168.6%